Cancer Pain - Pipeline Review, Q4 2010

Description: Cancer Pain - Pipeline Review, Q4 2010

Summary

Global Markets Direct's, "Cancer Pain Pipeline Review, Q4 2010", provides an overview of the Cancer Pain therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. "Cancer Pain-Pipeline Review 2010, Q4 2010" is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Cancer Pain.
- A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cancer Pain pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Cancer Pain.
- A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cancer Pain pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Cancer Pain
Cancer Pain Therapeutics under Development by Companies
Cancer Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Cancer Pain Therapeutics Development
Genzyme Corporation
Johnson & Johnson
Abbott Laboratories
Shionogi & Co., Ltd.
Ipsen S.A.
AcelRx Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
GW Pharmaceuticals plc
Mundipharma International Limited
Diamyd Medical AB
Orexo AB
Labtec GmbH
INSYS Therapeutics, Inc.
Immundrma Plc
Neurotune AG
WEX Pharmaceuticals Inc.
QRxPharma Limited
Xenome Ltd.
EUSA Pharma, Inc.
Mayo Clinic
Universities/Institutes Involved in Cancer Pain Therapeutics Development
Cancer Pain Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Abstral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fentanyl Sublingual Spray - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW-2000-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxycodone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-811717 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TA-8317 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tectin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Fentanyl TAIFUN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methadone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Morphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PecFent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tylenol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Cancer Pain - Featured News
Nov 23, 2010: GW Pharmaceuticals' Sativex Enters Phase III Clinical Program In Cancer Pain
Oct 01, 2010: AcelRx Completes End-Of-Phase II Meeting With FDA For ARX-02 For Treatment Of Cancer Pain
Sep 28, 2010: WEX Announces Update On Interim Analysis Of TEC-006 Clinical Trial With Tetrodotoxin
Sep 01, 2010: Afferent Reports Data Supporting Use Of P2X3 Antagonists In Reducing Bone Cancer Pain
Sep 01, 2010: Archimedes Pharma Receives European Marketing Authorization For PecFent For Treatment Of Cancer Pain
Aug 25, 2010: WEX To Present Clinical Data On Tetrodotoxin At 13th World Congress on Pain
Jun 25, 2010: Archimedes Pharma Receives CHMP Positive Opinion For PecFent For Treatment Of Breakthrough Cancer Pain
May 25, 2010: AcelRx Announces Positive Phase II Results Of ARX-02 Sufentanil NanoTab For Treatment Of Cancer Breakthrough Pain
Mar 30, 2010: Lpath Rejects Merck KGaA's Proposal To Extend Opt-in Deadline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering:
Order Online - http://www.researchandmarkets.com/reports/1474157/
Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cancer Pain - Pipeline Review, Q4 2010
Web Address: http://www.researchandmarkets.com/reports/1474157/
Office Code: SCD27F79

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World